Focused ultrasound-enabled brain tumor liquid biopsy (FUS-LBx) supplement

聚焦超声脑肿瘤液体活检 (FUS-LBx) 补充剂

基本信息

批准号：
10448708
负责人：
Hong Chen
金额：
$ 13.54万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-19 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10448708
关键词：
Address Animals Applications Grants Automobile Driving Biological Markers Biopsy Blood Blood - brain barrier anatomy Blood Circulation Brain Brain Diseases Brain Neoplasms Cardiovascular system Clinical Clinical Management DNA Data Detection Development Devices Diagnosis Disease Excision Family suidae Focused Ultrasound Future Goals Histologic Image Learning Liquid substance Location Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of brain Medical Microbubbles Molecular Molecular Profiling Monitor National Institute of Biomedical Imaging and Bioengineering Operative Surgical Procedures Parents Patient Monitoring Patients Polymerase Chain Reaction Proteins Public Health RNA Research Risk Sampling Small Business Innovation Research Grant Small Business Technology Transfer Research Spectrum Analysis Techniques Tissues Tumor Markers Tumor-Derived United States United States National Institutes of Health Work base clinical translation commercialization controlled release design detection method digital extracellular vesicles liquid biopsy neoplastic cell neuroimaging next generation sequencing novel patient population pre-clinical programs safety and feasibility tool treatment response tumor tumor progression

项目摘要

PROJECT SUMMARY/ABSTRACT This application is for the NIBIB C3i Accell program. The objective of our parent R01 application (R01EB030102, Project Period: 08/01/2020–04/30/2024) is to perform small animal and large animal studies to obtain compelling preclinical evidence needed to support future clinical translation of focused ultrasound-enabled liquid biopsy (sonobiopsy). Through learnings from NIBIB’s C3i programs, we identified that one key risk toward commercialization of our technique is the need to optimize the design of the sonobiopsy device for clinical use and validated its feasibility and safety in biomarker release. The objective of our proposed research for the C3i Accell program is to address this key technical risk. Successful completion of this work will obtain data that will support our start-up company’s NIH SBIR/STTR grant application to further commercial development efforts.

项目概要/摘要此应用程序适用于 NIBIB C3i Accell 计划我们的父 R01 应用程序的目标。（R01EB030102，项目期间：08/01/2020–04/30/2024）将进行小动物和大型动物研究获得支持聚焦超声未来临床转化所需的令人信服的临床前证据通过从 NIBIB 的 C3i 项目中获得的经验，我们发现了一项关键风险。为了实现我们技术的商业化，需要优化声活检设备的设计用于临床并验证其在生物标志物释放方面的可行性和安全性。 C3i Accell 计划的研究就是为了解决这一关键技术风险，成功完成这项工作将。获取数据支持我们的初创公司的 NIH SBIR/STTR 拨款申请以进一步商业化发展努力。